Serum Level of IL31,33 and 36 in Egyptian Paients With Psoriasis

• Conditions: Psoriasis

• Registration Number: NCT04344574
• Lead Sponsor: Assiut University

Brief Summary

Evaluating Serum Level Of IL 31 , IL33 and IL36 and Their Correlation with Disease Activity In Patients With Psoriasis In Assuit University Hospital .

* To correlate their levels with disease activity using PASI score .

* To allow better understanding of the pathophysiological mechanism of the disease .

Detailed Description

Serum samples will be collected from 45 psoriasis patients and 45 matched healthy individuals. After full history taking and dermatological examination, the disease severity will be assessed using the psoriasis area and severity index (PASI) score. All patients enrolled in our study had no other autoimmune or systemic diseases and underwent no systemic treatment including glucocorticoids, immunosuppressive drugs, or phototherapy at least 1 month before the PASI score evaluation and sample collection period. Wriiten informed consent will be obtained from all the patients and healthy controls.

Assessment of serum interleukin-31 ,33 and 36 concentrations in psoriatic patients Patients and controls Blood samples will collected from psoriatic patients and controls, and will centrifuged for 15 min at 1000 rpm. Next, the serum samples will be subdivided into small aliquots to be stored at -80°C until analysis for cytokine levels. ELISA kits will be used to determine serum IL-31 , 33 and 36

Study Timeline

• Status Verified: 2020-04
• Study First Submitted: 2020-04-01
• Study First Submitted QC: 2020-04-09
• Last Update Submitted: 2020-04-09
• Study First Posted: 2020-04-14
• Last Update Posted: 2020-04-14
• Study Start: 2020-06-01
• Primary Completion: 2021-06-01
• Study Completion: 2021-07-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

• Patients with all types of psoriasis.
• healthy volunteers without a family history of psoriasis or other autoimmune disease.

Exclusion Criteria

• other autoimmune , other chronic inflammatory or systemic diseases.
• cases received glucocorticoids, immunosuppressive drugs at least 1 month before sample collection .

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
4. Knowing the extent of disease activity by Psoriasis Area and Severity Index (PASI) score.	Baseline	assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease).
describe the serum levels of IL31, IL33 and IL36 in egyptian patients with psoriasis.	Baseline	1. Blood samples will collected from psoriatic patients and controls.; 2. using ELISA kits to measure serum concentration of IL31 \[pg/ml\] , IL33 \[pg/ml\] and IL36 \[pg/ml\] .; 3. p value less than 0,05 reflect significant increase in serum levels of measured interleukins.

Secondary Outcome Measures

Name	Time	Method
serum level of interleukins reflect severity of disease and represent anovel target for antipsoriatic drug theraby.	Baseline	increase of the serum level of interleukins during disease activity means significant increase which has a value in drug therapy of psoriasis . and vice versa.